BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) first clinical sites activated,

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

BLTEBelite Bio2026-08-13 01:45 EST

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

MLYSMineralys Therapeutics2026-08-11 20:05 EST

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SGMTSagimet Biosciences2026-08-11 11:30 EST

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
1.10 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States